Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTK | ISIN: US1407551092 | Ticker-Symbol: 69C
Tradegate
26.07.24
16:09 Uhr
0,338 Euro
-0,004
-1,29 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3400,34426.07.
0,3380,34626.07.

Aktuelle News zur CARA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.07.What's Going On With Cara Therapeutics Stock?8
11.07.Cara Therapeutics, Inc. Announces Exploration of Strategic Alternatives4
11.07.Cara Therapeutics To Explore Strategic Alternatives3
18.06.Cara Therapeutics announces 70% reduction in workforce11
18.06.Cara Therapeutics, Inc. - 8-K, Current Report4
13.06.These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'15
13.06.Why Is Cara Therapeutics (CARA) Stock Down 27% Today?10
13.06.Analyst Ratings For Cara Therapeutics7
13.06.Cara Therapeutics discontinues neurological condition study as drug fails7
12.06.Cara Therapeutics discontinues study on a neurological condition as drug fails3
12.06.Cara Therapeutics, Inc.: Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica84- Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo - - Company will discontinue clinical program in NP and explore strategic alternatives - STAMFORD, Conn., June...
► Artikel lesen
07.06.Cara Therapeutics, Inc. - 8-K, Current Report4
14.05.In-Depth Examination Of 5 Analyst Recommendations For Cara Therapeutics13
13.05.Cara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary5
13.05.Cara Therapeutics, Inc. - 10-Q, Quarterly Report2
13.05.Cara Therapeutics, Inc. - 8-K, Current Report1
13.05.Cara Therapeutics, Inc.: Cara Therapeutics Reports First Quarter 2024 Financial Results177STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...
► Artikel lesen
10.05.Cara Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview 4
06.05.Cara Therapeutics, Inc. to Announce First Quarter 2024 Financial Results on May 13, 20246
06.05.Cara Therapeutics, Inc.: Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 20246
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3